3 unknown. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Unknown 3 |
| Phase 2 | 1 | Unknown 1 |
Follow Refractory or Relapsed Multiple Myeloma: new trials by email Literature Review of Refractory or Relapsed Multiple Myeloma trials Research Report on Refractory or Relapsed Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| LCAR-B4822M-02 Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma LCAR-B4822M CAR-T Cell Immunotherapy - Refractory or Relapsed Multiple Myeloma | Phase 1 | Unknown | Second Affiliated Hospital of Xi'an Jiaotong University | 10 | 2018-07-26 | 2018-12-14 |
| Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma CAR-BCMA T cells, Fludarabine, Cyclophosphamide - Refractory or Relapsed Multiple Myeloma | Phase 1 | Unknown | First Affiliated Hospital of Zhejiang University | 11 | 2018-03-23 | 2020-10-08 |
| LCAR-B38M Cells in Treating Relapsed/Refractory (R/R) Multiple Myeloma LCAR-B38M CAR-T cell injection - Refractory or Relapsed Multiple Myeloma | Phase 1 / Phase 2 | Unknown | Nanjing Legend Biotech Co. | 100 | 2015-10-02 | 2023-06-12 |
Multiple Myeloma (3)
Blood Protein Disorders (3) · Cardiovascular Diseases (3) · Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Hemorrhagic Disorders (3) · Hemostatic Disorders (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Plasma Cell (3) · Paraproteinemias (3) · Vascular Diseases (3)
Cyclophosphamide (1) · fludarabine (1)
First Affiliated Hospital of Zhejiang University (1) · Nanjing Legend Biotech Co. (1) · Second Affiliated Hospital of Xi'an Jiaotong University (1)
China (2)
Haitao Meng, MD (1) · Jie Jin, MD (1) · Wan-Hong Zhao, MD, PhD (1)